This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
12 - 14 Nov 2024
Hamburg Congress CentreHamburg, Germany

Dave Madge, PhD
Vice President, Research Services Division at WuXi AppTec


Dr Dave Madge is Vice President of Discovery Services in WuXi AppTec. In this role Dave leads business development in Europe and Israel, alongside a portfolio of strategic initiatives across multiple therapeutic areas and modalities.

Prior to joining WuXi AppTec, in 2014, Dave was VP, Research, for the ion channel drug discovery company Xention Ltd, in Cambridge, UK, developing new molecules for cardiovascular and respiratory disorders. Before Xention Dave was based at University College London, as part of an integrated biomedical research group, and was responsible for developing new therapeutic discovery projects into funded biotech companies.

Dave has a PhD in Medicinal Chemistry from Imperial College, London, and started his career at The Wellcome Foundation in the medicinal chemistry team.

Agenda Sessions

  • Creating a Comprehensive Toolbox for Oligonucleotide Drug Discovery and Development